The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Vaxxas Named Concept Stage Winner of United States’ BARDA Prize for Advancing Microarray Patches for Vaccination
Jan 13, 2025•over 1 year ago
Contract Type
partnership
BrisbaneBiotechnology
Description
Vaxxas, a clinical-stage biotechnology company, has been named a Concept Stage winner of the United States Biomedical Advanced Research and Development Authority’s (BARDA’s) $50 million Patch Forward Prize. As part of the initial Concept Stage, Vaxxas will receive US$2 million (AU$3.2 million) from BARDA to accelerate its work advancing the company’s HD-MAP technology for administration of a COVID-19 mRNA vaccine. Vaxxas will collaborate with The University of Queensland’s world-leading mRNA research and manufacturing BASE facility to advance this program during 2025.
Company Information
Company
Vaxxas
Location
Brisbane, Queensland, Australia
About
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
BrisbaneBiotechnology